Apimeds Pharmaceuticals US, Inc. (APUS)
About Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$6.0M
- Total assets
- $164.2M
- Market cap
- $19.2M
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $11.9M
- Operating income
- -$11.9M
- Net income
- -$6.0M
- EPS (basic)
- $-0.55
- EPS (diluted)
- $-0.55
Balance sheet
- Total assets
- $164.2M
- Current assets
- $14.0M
- Total liabilities
- $10.8M
- Current liabilities
- $10.7M
- Shareholders’ equity
- $153.3M
Cash flow
- Operating cash flow
- -$8.9M
- Investing cash flow
- -$10.1M
- Financing cash flow
- $20.6M
- Net cash flow
- $1.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $19.2M
- EPS (diluted)
- $-0.55
- Shares outstanding
- 3.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 9, 2025
Apimeds Pharmaceuticals US, Inc. (APUS) Stock Price
- Reported a net loss of $6.0M.
- Trading 85% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Apimeds Pharmaceuticals US, Inc..
Write a review
News about Apimeds Pharmaceuticals US, Inc.
News & sentiment via Polygon.io
Apimeds Pharmaceuticals US, Inc.: frequently asked questions
Is Apimeds Pharmaceuticals US, Inc. an American company?
Apimeds Pharmaceuticals US, Inc. is a US-based company headquartered in Matawan, New Jersey, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Apimeds Pharmaceuticals US, Inc. headquartered?
Apimeds Pharmaceuticals US, Inc. is headquartered in Matawan, New Jersey, United States.
Is Apimeds Pharmaceuticals US, Inc. publicly traded?
Yes — Apimeds Pharmaceuticals US, Inc. is a publicly traded company. Its stock trades under the ticker symbol APUS on the NYSE.
What does Apimeds Pharmaceuticals US, Inc. do?
Apimeds Pharmaceuticals US, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
